rs199476349
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000216124.10(ARSA):c.883G>A(p.Gly295Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00000616 in 1,461,182 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G295C) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000216124.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ARSA | NM_000487.6 | c.883G>A | p.Gly295Ser | missense_variant | 5/8 | ENST00000216124.10 | NP_000478.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ARSA | ENST00000216124.10 | c.883G>A | p.Gly295Ser | missense_variant | 5/8 | 1 | NM_000487.6 | ENSP00000216124 | P1 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD3 exomes AF: 0.0000121 AC: 3AN: 248784Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 134948
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461182Hom.: 0 Cov.: 35 AF XY: 0.00000825 AC XY: 6AN XY: 726920
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
Metachromatic leukodystrophy Pathogenic:6Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Aug 09, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The ARSA c.883G>A (p.Gly295Ser) variant (previously reported as c.887G>A, p.Gly293Ser) has been reported in two studies in which it was found in a compound heterozygous state with a second missense variant in a total of three individuals with metachromatic leukodystrophy (Berna et al. 2004; Biffi et al. 2008). One of the compound heterozygous individuals was also heterozygous for two additional variants (one known phenotype modifier and one functional polymorphism known to reduce enzyme activity) but did not carry the most common pseudodeficiency alleles (Biffi et al. 2008). Control data are unavailable for this variant, which is reported at a frequency of 0.00003 in the European (non-Finnish) population of the Exome Aggregation Consortium. However, this frequency is based on two alleles only in a region of good sequence coverage, suggesting the variant is rare. The p.Gly295Ser variant is located in a conserved residue in a functionally important domain of the protein. Functional studies in BHK-21 cells demonstrated the variant to be a null allele, causing the complete loss of enzyme activity (Berna et al. 2004). Based on the evidence, the p.Gly295Ser variant is classified as likely pathogenic for arylsulfatase A deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 11, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects ARSA function (PMID: 15326627). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSA protein function. ClinVar contains an entry for this variant (Variation ID: 68154). This variant is also known as Gly293Ser. This missense change has been observed in individual(s) with metachromatic leukodystrophy (PMID: 15326627, 18786133). This variant is present in population databases (rs199476349, gnomAD 0.003%). This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 295 of the ARSA protein (p.Gly295Ser). - |
Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Oct 28, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 18, 2023 | Variant summary: ARSA c.883G>A (p.Gly295Ser) results in a non-conservative amino acid change in the encoded protein sequence. Three of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 248784 control chromosomes. c.883G>A has been reported in the literature in multiple compound heterozygous individuals affected with Metachromatic Leukodystrophy, including with adult and early juvenille onset (e.g. Berna_2004, Biffi_2008, Santhanakumaran_2022). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in null enzyme activity in vitro (e.g. Berna_2004). The following publications have been ascertained in the context of this evaluation (PMID: 15326627, 18786133, 36240581). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic (n=4) or likely pathogenic (n=2). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 19, 2021 | - - |
not provided, no classification provided | in vitro | Gelb Laboratory, University of Washington | - | - - |
not provided Pathogenic:3Other:1
not provided, no classification provided | literature only | UniProtKB/Swiss-Prot | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 25, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 30, 2024 | Published functional studies found G295S is associated with no detectable ARSA activity (PMID: 15326627); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Previously reported as G293S due to the use of alternate nomenclature; This variant is associated with the following publications: (PMID: 33185815, 15326627, 31418856, 34302356, 34055681, 18786133) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at